New daily pill aims to outperform standard HIV therapy in landmark trial
NCT ID NCT07711223
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests a new experimental drug, ACC017, taken once daily alongside two other HIV medications (FTC/TAF), in adults with HIV-1 who have never been treated before. The goal is to see if ACC017 is as safe and effective as the current standard drug dolutegravir at lowering the amount of virus in the blood. Participants will be randomly assigned to receive either ACC017 or dolutegravir for 48 weeks, and then all will switch to ACC017 for another 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called ACC017, taken as a tablet once daily, combined with emtricitabine/tenofovir alafenamide (FTC/TAF)
- What this could lead to
- If successful, ACC017 could offer a new once-daily treatment option for people starting HIV therapy, potentially with similar or better viral suppression than current standard care.
- What could go wrong
- This is an early-to-mid stage trial (Phase 1/2), so the drug's safety and effectiveness are not yet proven. It may not work as well as dolutegravir or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION, HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Ditan Hospital Capital Medical University, Beijing, China
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.